Adrian Santamaria, MD
Neurology · Tomball, TXNPI 1346444932
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $91,015 of the $140,946 with a category attached, or 64.6%. Jazz Pharmaceuticals Inc. accounts for 63.3% of it on its own, with 46 other manufacturers making up the rest. Among neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 651 payments — averaging $216.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$89K
- Avadel CNS Pharmaceuticals, LLC$23K
- Inspire Medical Systems, Inc.$10K
- Axsome Therapeutics, Inc.$10K
- Harmony Biosciences LLC$2K
- Medtronic$962
- plus $5K from 41 others
Across 24 payments — averaging $8179.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Avadel CNS Pharmaceuticals, LLC$149K
- Harmony Biosciences LLC$48K
What the payments were for
- Consulting fees$22,13716%
- Speaking & faculty fees$91,01565%
- Travel & lodging$12,6189%
- Food & beverage$14,65910%
- Education$5170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$140,946 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 70 | $1,079,050 |
| Sodium Oxybate | 30 | $534,509 |
| WakixPitolisant Hcl | 15 | $242,486 |
| LumryzSodium Oxybate | 21 | $191,206 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 22 | $169,991 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 26 | $81,094 |
| CopaxoneGlatiramer Acetate | 14 | $80,339 |
| Nurtec OdtRimegepant Sulfate | 28 | $42,727 |
| RytaryCarbidopa/Levodopa | 26 | $33,684 |
| NeuproRotigotine | 16 | $33,647 |
| AptiomEslicarbazepine Acetate | 13 | $30,661 |
| FycompaPerampanel | 13 | $18,433 |
| Aimovig AutoinjectorErenumab-Aooe | 18 | $14,756 |
| Lacosamide | 73 | $7,267 |
| FingolimodFingolimod Hcl | 11 | $6,696 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $2,321 | $242,48615 claims |
| Avadel CNS Pharmaceuticals, LLCLumryz | $23,136 | $191,20621 claims |
| Grifols USA, LLCGamunex-C | $129 | $81,09426 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $213 | $80,33914 claims |
| PfizerNurtec Odt | $218 | $42,72728 claims |
| Amneal Pharmaceuticals LLCRytary | $151 | $33,68426 claims |
| UCB, Inc.Neupro | $107 | $33,64716 claims |
| Eisai Inc.Fycompa | $459 | $18,43313 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $19 | $5,32911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 neurology providers in Texas.
Other neurology in Tomball
- Ann BassSan Antonio$1.7M
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Benjamin GreenbergDallas$773K
- Annette OkaiPlano$730K
- Waleed El-FekyDallas$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.